Two stocks in Healthcare
Genus vs Smith & Nephew: profit, growth, debt and price compared
Smith & Nephew is stronger on 4 of 7 figures: sales growth, price for its expected profit, dividend and price trend. Genus is stronger on 3: profit margin, debt and analysts' view.
Save both stocks to your watchlist and revisit their latest fundamentals.
| GenusGNS.L | Smith & NephewSN.L | |
|---|---|---|
| Net margin | Stronger: 43.4% | 10.1% |
| Revenue growth, past year | −4.10% | Stronger: +4.60% |
| Debt to equity | Stronger: 14.0% | 73.1% |
| Forward P/E | 18.5× | Stronger: 13.2× |
| Dividend yield | 1.56% | Stronger: 2.55% |
| Analysts | Stronger: Buy · 13 | Hold · 17 |
| From its 200-day average | −7.1% | Stronger: +1.4% |
Share price over the past year
- Genus−14.3%
- Smith & Nephew−6.8%
20 Nov 202518 Nov 2026
Genus or Smith & Nephew: which is stronger?
- GNS.L
Which is more profitable?
Genus keeps more of each sale as profit: 43.4% against 10.1%.
- SN.L
Which is growing its sales faster?
Smith & Nephew is growing its sales faster: +4.60% over the past year, against −4.10%.
- GNS.L
Which has borrowed less?
Genus has borrowed less: its debt is 14.0% of what its shareholders own, against 73.1% for Smith & Nephew.
- SN.L
Which costs less for the profit it is expected to make?
Smith & Nephew costs less for the profit it is expected to make: 13.2× its forward earnings, against 18.5×.
- SN.L
Which pays more in dividends?
Smith & Nephew pays more back in dividends for what a share costs: 2.55% a year, against 1.56%.
- GNS.L
Which do analysts rate higher?
Analysts are warmer on Genus: Buy, against Hold for Smith & Nephew.
- SN.L
Which is in the stronger price trend?
Smith & Nephew's price is in the stronger trend: 1.4% above its 200-day average, against 7.1% below.
What each company does
GNS.LGenus
Genus plc produces and sells animal genetics to farmers in North America, Latin America, the United Kingdom, the rest of Europe, the Middle East, Russia, Africa, and Asia.
Reports results on 25 February 2027
SN.LSmith & Nephew
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally.
Reports results on 1 March 2027
This comparison is just the starting point.
Discover opportunities, understand companies and compare investments in one place. See how StratDeck works
Keep researching
Where next
More comparisons
Free email
Up to speed in minutes, four times a week
Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.
Early access
Become a StratDeck founding user
Use StratDeck, tell us what's missing, and help decide what we build next.
100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.